Avior Wealth Management LLC Raises Position in Ascendis Pharma A/S (NASDAQ:ASND)

Avior Wealth Management LLC grew its position in Ascendis Pharma A/S (NASDAQ:ASND) by 9.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 7,822 shares of the biotechnology company’s stock after purchasing an additional 645 shares during the quarter. Avior Wealth Management LLC’s holdings in Ascendis Pharma A/S were worth $985,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Goldman Sachs Group Inc. grew its position in Ascendis Pharma A/S by 3,024.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,754,458 shares of the biotechnology company’s stock valued at $205,903,000 after buying an additional 1,698,302 shares during the period. T. Rowe Price Investment Management Inc. grew its position in Ascendis Pharma A/S by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,828,267 shares of the biotechnology company’s stock valued at $345,417,000 after buying an additional 796,087 shares during the period. Wellington Management Group LLP grew its position in Ascendis Pharma A/S by 14.6% during the first quarter. Wellington Management Group LLP now owns 4,665,579 shares of the biotechnology company’s stock valued at $547,552,000 after buying an additional 594,855 shares during the period. Capital International Investors bought a new stake in Ascendis Pharma A/S during the first quarter valued at approximately $28,894,000. Finally, Massachusetts Financial Services Co. MA grew its position in Ascendis Pharma A/S by 16.3% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,264,470 shares of the biotechnology company’s stock valued at $118,405,000 after buying an additional 176,948 shares during the period.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $142.17 on Thursday. Ascendis Pharma A/S has a one year low of $66.03 and a one year high of $161.00. The company’s fifty day moving average price is $149.17 and its 200-day moving average price is $123.75. The company has a market capitalization of $8.28 billion, a PE ratio of -15.37 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, topping the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. The firm had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. On average, research analysts predict that Ascendis Pharma A/S will post -4.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ASND. Jefferies Financial Group began coverage on shares of Ascendis Pharma A/S in a research report on Wednesday, December 20th. They set a “buy” rating and a $150.00 target price for the company. Wells Fargo & Company lifted their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a report on Monday, April 1st. JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a report on Tuesday, April 2nd. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Monday, December 25th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.25.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.